SCHEMBL43553

SCHEMBL43553

NC(=O)c1cccc(-c2ccccc2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 3/20 0.70
KMO O15229 1/20 0.67
PRSS1 P07477 1/20 0.64
PRSS2 P07478 1/20 0.64
PRSS3 P35030 1/20 0.64
PARP1 P09874 6/20 0.62
POLB P06746 1/20 0.62
CYP3A4 P08684 1/20 0.62
MAPT P10636 1/20 0.62
TSHR P16473 1/20 0.62
CYP2C19 P33261 1/20 0.62
RECQL P46063 1/20 0.62
BLM P54132 1/20 0.62
PMP22 Q01453 1/20 0.62
HSD17B10 Q99714 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
HDAC8 Q9BY41 1/20 0.60
ERN1 O75460 1/20 0.57
MKNK1 Q9BUB5 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29788172 1.00 DHODH (0.70) DHODHKMOPRSS1PRSS2PRSS3
Bromide SCHEMBL30159854 0.98 DHODH (0.68) DHODHKMOPRSS1PRSS2PRSS3
Hydrogen Sulfide SCHEMBL27914334 0.98 DHODH (0.68) DHODHKMOPRSS1PRSS2PRSS3
Hydrochloric Acid SCHEMBL3973404 0.98 DHODH (0.68) DHODHKMOPRSS1PRSS2PRSS3
SCHEMBL29941476 0.98 DHODH (0.68) DHODHKMOPRSS1PRSS2PRSS3
Hydrochloric Acid SCHEMBL30628442 0.98 DHODH (0.68) DHODHKMOPRSS1PRSS2PRSS3
SCHEMBL6999225 0.96 DHODH (0.63) DHODHKMOPRSS1PRSS2PRSS3
SCHEMBL2431097 0.93 PARP1 (0.64) DHODHKMOPRSS1PRSS2PRSS3
SCHEMBL31422694 0.93 PARP1 (0.64) DHODHKMOPRSS1PRSS2PRSS3
Phosphoric Acid SCHEMBL19385047 0.92 DHODH (0.62) DHODHKMOPRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 401 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024259171-A9 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2025-01-23 WO claimed
CN-119192174-A Novel biphenyl carboxylic FXR agonist, preparation method thereof and application thereof as medicine 广东药科大学 2024-12-27 CN claimed
CN-119186425-A Micro-reactor reaction channel structure, preparation method, preparation system and application of solid acid catalyst 中国石油化工股份有限公司 2024-12-27 CN claimed
CN-119192440-A Butene hydration catalyst and preparation method and application thereof 中国石油化工股份有限公司 2024-12-27 CN claimed
US-12168014-B2 Method for treating cancer Epizyme, Inc. (US) 2024-12-17 US claimed
WO-2024146870-A1 COMPOSITIONS FOR HORMONALLY IMPACTED SKIN THE BOOTS COMPANY PLC (GB) 2024-07-11 WO claimed
CN-118206465-A Novel biphenyl carboxylic acid FABP1 inhibitor, preparation method thereof and application thereof as medicine 广东药科大学 2024-06-18 CN claimed
WO-2024121709-A1 PAPAIN-LIKE PROTEASE (PLPRO) INHIBITORS PFIZER INC. (US) 2024-06-13 WO claimed
CN-118076602-A Heteroaryl-acetylenes, pharmaceutical compositions thereof and their therapeutic uses 嘉兴优博生物技术有限公司 2024-05-24 CN claimed
CN-114630819-B Benzamide derivative for preventing or treating cancer, method for preparing the same, and pharmaceutical composition comprising the same as active ingredient 韩国化学研究院 2024-02-13 CN claimed
WO-2005021558-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2005-03-10 WO claimed
EP-1509497-A1 CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES Amgen Inc. (US) 2005-03-02 EP claimed
WO-2004099127-A1 NOVEL COMPOUNDS AS KINASE INHIBITORS NOVO NORDISK A/S (DK) 2004-11-18 WO claimed
WO-2004093872-A1 3-OXO-1, 3-DIHYDRO-INDAZOLE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS PHOSPHOLIPASE INHIBITORS ELI LILLY AND COMPANY (US) 2004-11-04 WO claimed
EP-1453789-A2 N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES Elan Pharmaceuticals, Inc. (US) 2004-09-08 EP claimed
WO-2003099776-A1 CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES AMGEN INC. (US) 2003-12-04 WO claimed
WO-2003040096-A2 N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES ELAN PHARMACEUTICALS, INC. (US) 2003-05-15 WO claimed
CN-1400973-A Novel biarylcarboxamides ASTRAZENECA AB (SE) 2003-03-05 CN claimed
EP-0460083-A1 DERIVATIVES OF N-PHENYLBENZAMIDE WITH ANTI-ULCER AND ANTI-ALLERGY ACTIVITY AND A METHOD FOR THEIR PREPARATION. ROTTA RESEARCH LAB (IT) 1991-12-11 EP claimed
WO-1990009989-A1 DERIVATIVES OF N-PHENYLBENZAMIDE WITH ANTI-ULCER AND ANTI-ALLERGY ACTIVITY AND A METHOD FOR THEIR PREPARATION ROTTA RESEARCH LABORATORIUM S.P.A. (IT) 1990-09-07 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12168014-B2 Method for treating cancer EZH2, BMI1, EZH1 DHODH 1954/4885KMO 3473/4885PRSS1 2584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.